Bausch Health Companies Inc. (NYSE:BHC) inches down 1.46% to trade at $6.41 on Friday after it will report third-quarter financial results on Thursday, November 3, 2022. At 8:00 a.m. U.S. EDT, Bausch Health will hold a conference call and live webcast to discuss the results and offer a business update. All materials will be made accessible on the Bausch Health website’s Investor Relations section prior to the commencement of the call.
The Company’s shareholders adopted revisions to the Amended and Restated 2014 Omnibus Incentive Plan at the Company’s annual meeting on June 21, 2022. The Company has relied on the exemption for “Eligible Interlisted Issuers” under Section 602.1 of the Toronto Stock Exchange Company Manual, which has the effect of exempting the Company from certain Canadian requirements in connection with the Plan, subject to the satisfaction of certain conditions prescribed by the TSX.
On the other side, Bausch Health Companies Inc. (NYSE:BHC) is continuing its commitment to improve lives with the release of changes to the Tabular Index from the Centers for Medicare & Medicaid Services, especially for the prevention and treatment of SAD (CMS). All suitable codes for SAD have now been merged into a bundle, allowing healthcare providers to further define a diagnosis in an easy-to-understand index tab and transmit all SAD diagnoses to one simple code: F33. This breakthrough contributes to the further definition of SAD as a diagnosable and treatable illness.
SAD affects around 16 million people in the United States alone. 1,2 While the symptoms of SAD can be similar to those of Major Depressive Disorder (MDD), many persons with SAD may experience these symptoms more frequently during the fall or winter months and may benefit from a medication that does not need year-round use. 3-6
Prior to this significant Tabular Index adjustment, it is considered that SAD was underdiagnosed7, and the ICD-10 is utilized to appropriately categorize an illness and diagnosis. As of October 1, 2022, healthcare providers will have access to a new instructional note for SAD at F33 in the Tabular Index, allowing patients to be more accurately recognized and prescribed an FDA-approved SAD medication.
